Retrospective study shows manual dose rounding reduces drug wastage and costs in HER2-positive breast cancer, indicating a need for innovative economic solutions.
Key Points
The study aims to assess the impact of manual dose rounding on drug wastage and costs for T-DM1 in breast cancer treatment.
Retrospective study design analyzing patient data from January 2015 to December 2022.
Included patients treated with T-DM1 at Tampere University Hospital.
Data collected from chemotherapy and pharmacy software.
Analyzed drug wastage and cost savings due to dose rounding.
1797 doses of T-DM1 were analyzed over 8 years.
Average of 67% of doses were suitable for rounding.
31,268 mg of drug waste (74% of total) was reduced through dose rounding.
Total savings amounted to 1,307,659€ (14% of costs).
Potential savings of an additional 609,028€ if all doses had been rounded down.